Preview

Obstetrics, Gynecology and Reproduction

Advanced search

Obstetrics, Gynecology and Reproduction(“Akuserstvo, Ginekologia i Reprodukcia”) is a scientific and practical peer-reviewed journal for obstetricians, gynecologists and other experts in the area of women’s health. Our aims and priorities focus on scientific and information support to the members of the "professional community" in their pursuit of new ideas in obstetrics and gynecology research. In addition, the AGR journal proudly contributes to the continuing medical education (CME) of practitioners who specialize in various areas of women’s health including obstetrics, gynecology, in vitro fertilization (IVF) and assisted reproductive technology (ART).

Obstetrics, Gynecology and Reproduction (“Akuserstvo, Ginekologia i Reprodukcia”) was founded in 2007

The impact factor of this journal, as shown in the Russian Science Citation Index (RSCI) is among the highest for the periodicals on obstetrics, gynecology, perinatology and problems of women’s health. According to RSCI, the biennial impact factor was 0.509 in 2013, 0.810 in 2014, and 0.976 in 2015.

The journal publishes original articles on clinical and experimental studies, as well as reviews on obstetrics, gynecology, and human reproduction. Special attention is paid to publications on CME as well as historic aspects of obstetrics and gynecology. All manuscripts, both original research and literature reviews, are published upon a mandatory peer-review.

Languages: Russian, English

Periodicity: 6 issues per year. 

The printed versions are distributed under the Creative Commons Attribution 4.0 License: full-text materials are freely available to the public in an open access repository.


Distribution of the printed version: Russia, the EurAsian Economic Community (EurAsEC) countries (Belarus, Kazakhstan, Kyrgyzstan, Tajikistan, Uzbekistan, Armenia, Moldova), Ukraine, Georgia.

The editorial board of Obstetrics, Gynecology and Reproduction (“Akuserstvo, Ginekologia i Reprodukcia”) includes leading scientists from Russia, Austria, Great Britain, Israel, USA, Croatia, Ukraine, Georgia, and Uzbekistan.

The editorial board of this journal maintains the policy of full compliance with all principles of publishing ethics. Our ethical standards and codes conform to those of top international science publishers.

All submitted materials undergo a mandatory double-blind peer review.

Media Certificate of Registration: ПИ №FS77-34885 of December 29, 2008.
ISSN 2077-8333 (Print)
ISSN 2311-4088 (Online) 

By the decision of the Higher Attestation Commission (HAC) of Russia, Obstetrics, Gynecology and Reproduction (“Akuserstvo, Ginekologia i Reprodukcia”) is included in the "List of top peer-reviewed scientific journals and publications" where scientists seeking academic degrees are required to publish their results. 

The Obstetrics, Gynecology and Reproduction (“Akuserstvo, Ginekologia i Reprodukcia”) journal appears in the Russian Universal Scientific Electronic Library (RUNEB) elibrary.ru and is also present in the database of the Russian Science Citation Index (RSCI). Concise versions of major articles from this journal are published by the All-Russian Institute for Scientific and Technical Information (VINITI). The journal is also indexed by "Ulrich's periodicals Directory" – a global information system of periodicals and continued publications.

 

Current issue

Vol 19, No 2 (2025)

EDITORIAL

152-157 699
Abstract

This journal issue presents studies in the field of obstetrics, gynecology and reproductive medicine. The original articles consider the genetic aspects of preeclampsia, including the role of NOS3 gene rs1799983 polymorphism, modern approaches for predicting uterine fibroids using neural network technologies, and vasopressin value as a marker of premature birth. Particular attention is paid to personalized methods of treating coagulopathic bleeding based on thromboelastometry and pregnancy management in chronic kidney pathology. The review articles analyze the pharmacological properties of iron fumarate, the role of the ARID1A gene in gynecological oncology, microbiome impact on the effectiveness of assisted reproductive technologies and the pathogenesis of fetal inflammatory syndrome. Clinical observation describes a rare case of spontaneous uterine rupture, and a historical analysis of forgotten obstetric techniques is presented.

ОRIGINAL ARTICLES

What is already known about this subject?

► Preeclampsia (PE) is a hypertensive complication of pregnancy, referred to major obstetric syndromes. According to the timing of manifestation, early (up to 34 weeks of gestation) and late PE (from 34 weeks of gestation) are distinguished. In both cases, the key arm in the underlying pathogenesis is systemic endothelial dysfunction, similar to that developed in SARS-CoV-2 infection.

► Post-PE women are at risk of developing cardiovascular diseases, cognitive disorders, end-stage renal failure, thromboembolism, and diabetes mellitus, which are also associated with endothelial damage that persists long-term or even lifelong after PE resolution.

► The influence of the hereditary factor on PE development has been proven epidemiologically. The underlying gene has not been yet identified. However, a risk may increase upon carriage of polymorphic variants of some genes, including those controlling endothelium functioning.

What are the new findings?

► The association between the carriage of a polymorphic variant in NOS3 gene and РЕ development among women living in the Republic of Tatarstan (Russia) has been revealed.

► Susceptibility to SARS-CoV-2 infection during pregnancy is not affected by the carriage of NOS3 gene rs1799983 poly­morphism.

How might it impact on clinical practice in the foreseeable future?

► The identified genetic marker could potentially be applied as a part of comprehensive РЕ prediction models, including the preconception stage.

158-167 624
Abstract

Introduction. Preeclampsia (РЕ) is a complication of pregnancy resulting from a generalized vascular dysfunction. Systemic endotheliopathy also emerges due to a viral infection such as caused by SARS-CoV-2. A verified marker of endothelial damage is a decrease in endothelial cell-produced nitric oxide (NO) level. NOS3 is a gene encoding the enzyme endothelial nitric oxide synthase responsible for NO synthesis.

Aim: to assess an association between rs1799983 single nucleotide polymorphism in NOS3 gene and the risk of developing РЕ as well as susceptibility to SARS-CoV-2 infection during pregnancy in women living in the Republic of Tatarstan.

Materials and Methods. A case-control retrospective observational study with 416 women was conducted at the Sadykov City Clinical Hospital No. 7. Patients were divided into the following groups: group 1 – 119 patients with РЕ, without signs of viral infection; group 2 – 98 pregnant women with moderate SARS-CoV-2 infection without hypertensive disorders. Control group consisted of 199 pregnant women with normotension during gestation period, with no signs of viral infection. Maternal whole blood specimens were analyzed in the study. NOS3 gene rs1799983 polymorphism was genotyped using real-time polymerase chain reaction.

Results. A comparatively assessed prevalence of NOS3 gene rs1799983 genotypes demonstrated statistical significance between group of patients with РЕ and control group (p < 0.05). Carriage of the G allele and the G/G genotype in NOS3 gene rs1799983 polymorphism is associated with risk of developing РЕ. No association between carriage of NOS3 gene rs1799983 polymorphism and susceptibility to SARS-CoV-2 infection in pregnant women was observed (p > 0.05).

Conclusion. The study revealed the association between the carriage of NOS3 gene rs1799983 polymorphism and a risk of developing РЕ but not with SARS-CoV-2 susceptibility during pregnancy in women living in the Republic of Tatarstan.

What is already known about this subject?

► Cancer patients have a markedly higher risk of venous thromboembolic complications (VTE) compared to the general population, especially in the presence of metastases and undergoing antitumor therapy.

► A number of clinical scales and biomarkers have been used to predict VTE recurrence, but none of the models provides a fully individualized approach.

► The duration of anticoagulant therapy (ACT) for recurrent VTE in patients with malignant tumors remains a matter of debate, especially following the standard first six months of treatment.

What are the new findings?

► Vienna-CATS and Tic-Onco scales have high discriminatory ability in assessing the long-term risk of thrombosis recurrence in cancer patients.

► Personalized ACT lasting more than 5 years effectively prevents recurrent VTE in high-risk patients without prominently increasing risk of bleeding.

► A personalized algorithm for ACT in patients with oncological diseases, based on a combination of clinical and hematological data, D-dimer levels, assessment of renal function and presence of genetic thrombophilia forms, allows not only to optimize safety of therapy, but also to increase its effectiveness upon long-term use.

How might it impact on clinical practice in the foreseeable future?

► The use of the Vienna-CATS and Tic-Onco scales in routine practice will allow more precisely identify patients requiring long-term prophylaxis, including those who were not previously classified as high risk according to the Khorana scale.

► The study results may contribute to revising ACT timing in cancer patients with high risk of recurrent thrombosis in favor of extending it.

► Integration of thrombophilia genetic testing into risk assessment algorithms may become a standard for choosing a strategy for long-term ACT in oncology.

168-179 627
Abstract

Aim: to stratify the risk of thrombosis and assess frequency of recurrent venous thromboembolism (VTE) and bleeding during long-term anticoagulant therapy (АСТ) in patients with stage III–IV ovarian cancer (ОС).

Materials and Methods. A prospective interventional comparative non-randomized study was conducted by enrolling 126 patients with stage III–IV ОС, of whom 66 had VTE and received long-term АСТ for 60–72 months, whereas 60 subjects comprised comparison group without thrombotic complications. Risk stratification was performed using the Khorana, Vienna-CATS, and Tic-Onco scales. The frequency of VTE recurrence and bleeding as well as the prognostic significance of the above noted scales were assessed.

Results. It was found that recurrent VTE (deep vein thrombosis – in 12.1 %, pulmonary embolism – in 6.1 %) developed in 18.2 % of patients receiving anticoagulants, so that two thirds of cases occurred within the first year of therapy. In comparison group, VTE incidence was 16.7 %. Major bleeding was recorded in 6.1 % patients, clinically significant moderate bleeding – in 21.2 % cases. The Vienna-CATS (AUC = 0.719) and Tic-Onco (AUC = 0.730) scales demonstrated better predictive ability compared to Khorana model (AUC = 0.671).

Conclusion. 60–72-month-long АСТ in patients with high thrombotic risk allows to significantly reduce the frequency of VTE recurrence with acceptable level of hemorrhagic complications and can be considered as a preferred strategy for secondary prevention in active oncological processes.

What is already known about this subject?

► Uterine leiomyoma (UL) holds a leading position in the pattern of female genital organ diseases, being in second place among all gynecological diseases.

► Today, a paradigm shift in the approach to UL is required as well as development of a model for personalized primary and secondary prevention taking into consideration of the expected risk factors.

► Neural network analysis can become a promising tool for optimizing medical processes, which determines its usefulness and relevance in healthcare.

What are the new findings?

► A model for predicting the UL emergence using neural network analysis of risk factors is described, where the number of input neurons comprised 12 units; two hidden layers containing 5 and 7 units, and 2 output neurons (UL present/not present) are included.

► The prediction accuracy for the developed model was 92.3 %, sensitivity – 90.6 %, specificity – 94.2 %, which proves the promise of this method for clinical practice.

► ROC analysis characterizing the informativeness of neural network data analysis in the early UL diagnostics emphasizes the method predictive value: area under the curve = 0.93 (95 % confidence interval = 0.91–0.94; p < 0.001).

How might it impact on clinical practice in the foreseeable future?

► In the future, the developed model can be used for the early UL detection among women undergoing annual screening, which will shift from the established paradigm of radical treatment to a preventive approach.

► A deeper understanding of the tumor etiology will be а key to developing new methods for UL treatment and prevention.

180-191 684
Abstract

Aim: to create a model for predicting emergence of uterine leiomyoma (UL) using neural network analysis of risk factors and to evaluate its prognostic characteristics.

Materials and Methods. A retrospective case-control study with 209 patients aged 20–47 years was performed covering the years from 2022 to 2024. Two groups of patients were identified: 1 – 106 women with UL, 2 – 103 patients without UL. Preliminary data processing was carried out, followed by a quantitatively analyzed relationship between risk factors and UL development using neural network analysis. The multilayer perceptron method was used to create a prognostic model for predicting UL emergence.

Results. During the study, there were selected 12 model-based factors showing statistically significant inter-group differences: body mass index (BMI), age at menarche, number of abortions and spontaneous abortions, age at first birth, presence of arterial hypertension (AH), benign ovarian tumors, history of in vitro fertilization, level of anti-Müllerian hormone, number of pregnancies, serum cholesterol and glucose levels. The prediction accuracy for the developed model was 92.3 %, sensitivity – 90.6 %, specificity – 94.2 %. The predictive value was confirmed using ROC analysis – the area under the curve was 0.93 (95 % confidence interval = 0.91–0.94; p < 0.001), which proves the promise of this method for clinical practice. Modifiable and potentially modifiable factors included increased BMI, AH, benign ovarian tumors, cholesterol and glucose levels. Such factors are considered as most relevant, due to an opportunity to be directly or indirectly affected, which proves an importance for preventive approach to this disease.

Conclusion. The developed model is an effective tool for predicting UL emergence (accuracy 92.3%), the use of which in clinical practice will allow shifting from the established paradigm of radical treatment to a preventive approach.

What is already known about this subject?

► Vasopressin and oxytocin are two related neuropeptides that differ in just two amino acids. Vasopressin increases the tone of vascular smooth muscle walls, causes narrowing of arterioles, veins, venules as well as stimulates myometrial activity regardless of pregnancy.

► Russia-wide researchers in the field of obstetrics and gyneco­logy have proven the effect of tissue receptor sensitivity to vasopressin. The higher cognate receptor quantity, the worse the prognosis of adenomyosis with pelvic pain, which is manifested by spontaneous spastic myometrial dysperistaltic contractions.

What are the new findings?

► An increase in blood serum vasopressin concentration is directly proportional to an increase in the pain score assessed by visual analog scale (VAS).

► A dynamic decrease in vasopressin concentration from the baseline level by at least 2-fold in patients with threatened premature birth (РВ) suggests a pregnancy prolongation.

► An increase in vasopressin concentration from baseline level by at least 3-fold was found in patients with developed РВ.

How might it impact on clinical practice in the foreseeable future?

► Dynamic measurement of blood serum vasopressin concentration in relation to VAS-based pain score is accessible, objective, and cost-effective for predicting РВ outcome.

192-200 774
Abstract

Introduction. To date, premature birth (РВ) remains one of the main problems in modern obstetrics. The scientific world community continues to search for an affordable, universal, cost-effective method for РВ prediction, which served as the basis for conducting current study.

Aim: assessing an opportunity for diagnosing and predicting an outcome of threatened РВ by studying the blood serum vasopressin level in relation to changes in pain scores analyzed by visual analog scale (VAS). Materials and Methods. A prospective observational randomized study was carried out. In 120 pregnant women, vasopressin level in the venous blood serum was examined in relation to changes in VAS-based pain levels. Main group consisted of 65 patients with complaints of pulling pains in the lower abdomen upon admission to the obstetric hospital, 31 of them with threatened РВ, in whom pregnancy was preserved (main group A) and 34 who gave birth prematurely (main group B). The control group included 55 women with term delivery.

Results. During the development of spontaneous labor, blood serum vasopressin level dynamically increased that was directly proportional to rise in VAS-based pain scores. A statistically significant relation between changes in blood serum vasopressin level and outcome of threatened PB has been established. Thus, a dynamic decrease in vasopressin concentration from the baseline level in patients with threatened PB (from 0.323 ± 0.046 ng/ml to 0.158 ± 0.034 ng/ml) points at possibility of pregnancy prolongation, whereas increase in vasopressin concentration from the baseline level was noted in patients with PB (from 0.117 ± 0.020 ng/ml to 0.364 ± 0.070 ng/ml).

Conclusion. Studying the dynamics of blood serum vasopressin level allows to use this parameter for prediction of threatened PB outcome.

What is already known about this subject?

► Patients with chronic kidney disease (CKD) have an increased incidence of pregnancy complications compared to healthy women: preeclampsia (PE), intrauterine growth retardation, preterm labor and a need for operative delivery.

► Diurnal proteinuria does not exceed 300 mg level during physiological pregnancy course in healthy women. Proteinuria (PU) greater than 300 mg/day is one of PE signs, but in patients with CKD, pathological PU can be observed even without PE.

► In healthy women and in some patients with CKD, a gestational decrease in serum creatinine level is noted, most prominent in the second trimester of pregnancy.

What are the new findings?

► Among patients with chronic glomerulonephritis (CGN) compared to those suffering from chronic tubulointerstitial kidney diseases (CTID) during pregnancy, the percentage of women with PU > 1.0 g/day and patients with arterial hypertension was significantly higher, whereas percentage of patients with urinary tract infection was lower. The incidence of PE, placental insufficiency, preterm labor and caesarian section did not differ between groups.

► Virtually throughout entire pregnancy in patients with CGN vs. CTID, PU was significantly higher, but serum creatinine level did not differ between groups.

► In pregnant women with CGN who developed PE, early pregnancy PU was significantly elevated compared to patients without PE. However, in patients with CTID, early pregnancy PU did not differ between the preeclamptic and non-preeclamptic subgroups.

► In both patients with CGN and women with CTID, an increase in PU was observed from early gestation until the end of pregnancy (excepting stabilization period at 26–32 weeks of gestational age), whereas serum creatinine level decreased by 11–13 weeks, then stabilized, and after 26–28 weeks increased until delivery.

How might it impact on clinical practice in the foreseeable future?

► The presence of prominent PU in early pregnancy and its persistence throughout gestation in patients with CGN will assist in assessing an increased risk of superimposed PE. In patients with CTID, lack of PU in early pregnancy does not allow predicting the lack of superimposed PE.

► Interpretation of moderately increased serum creatinine level later than gestational age of 6 weeks as physiological changes (in the absence of major signs of РЕ and fetal distress) will allow avoid unjustified preterm delivery in patients with CKD.

201-215 595
Abstract

Introduction. Women with chronic kidney disease (CKD) have an increased incidence of pregnancy complications, but few comparative studies on features of pregnancy course during chronic glomerulonephritis (CGN) and chronic tubulointerstitial kidney disease (CTID) are available.

Aim: comparison the frequency of pregnancy complications, proteinuria (PU) and serum creatinine dynamics in patients with CGN and CTID.

Materials and Methods. We conducted an observational single-centre study enrolling 128 pregnant women with CGN (135 deliveries) and 138 with CTID (145 deliveries) by assessing the incidence of complications, diurnal PU, serum creatinine level starting from early gestation to delivery every 4–6 weeks.

Results. Favourable pregnancy outcome was observed in 94.8 % of patients with CGN and in 95.7 % with CTID. The incidence of preeclampsia (PE), placental insufficiency, acute kidney injury, and preterm delivery showed no not inter-group differences, but arterial hypertension, PU > 1.0 g/day were more common in CGN, whereas in CTID – urinary tract infections. During pregnancy, PU increased in both groups, and only in CGN in patients with PE early pregnancy PU was significantly higher than in those without PE. Both groups showed similar serum creatinine dynamics: decrease starting from early pregnancy stages, stabilization in the middle of pregnancy followed by elevation from 28–30 weeks of gestational age until delivery.

Conclusion. High PU level in early pregnancy may help to predict PE in CGN, but not in CTID. In patients with CKD, rise in PU along with serum creatinine increased up to baseline level in late pregnancy, are typically observed and without PE, fetal distress should not be considered as unambiguous indication for early delivery.

What is already known about this subject?

► The first coagulation factor that becomes decreased during bleeding and leads to coagulopathy is fibrinogen. The fibrinogen level in postpartum hemorrhage (PPH) can predict with a high degree of probability progression and severity of bleeding.

► Fibrinogen replenishment with cryoprecipitate and its control in massive obstetric hemorrhage is possible only by applying an algorithm based on viscoelastic tests.

► The use of thromboelastometry (TEM) parameters and knowledge of their correlation with coagulation tests allows avoiding unnecessary transfusions.

What are the new findings?

► The relationship between coagulation test parameters, TEM parameters and blood loss volume allows to predict the necessary plan of action for PPH.

► If the blood loss volume is up to 2000 ml, transfusion therapy is not always required; upon specific needs, prothrombin concentrates can be used.

► In case of bleeding in obstetric patients, transfusion of platelet concentrate is required in extremely rare cases.

How might it impact on clinical practice in the foreseeable future?

► Improving the algorithm for treating massive obstetric hemorrhage using thromboelastometry parameters will allow for rapid identification or elimination of hemostasis defects and its proper correction.

► Targeted therapy of obstetric hemorrhage will reduce number of unnecessary transfusions and improve course of postpartum period.

216-229 741
Abstract

Aim: to justify a differentiated approach to the treatment of obstetric coagulopathic bleeding depending on the nature of hemostasis disorders.

Materials and Methods. A prospective cohort study was conducted involving 52 patients with postpartum hemorrhage (PPH) who gave a child birth between 2021 and 2023. Diagnostics and treatment of coagulopathy was carried out according to the algorithm using thromboelastometry (TEM) parameters. Patients were divided into 3 groups depending on blood loss volume: group 1 (n = 19) – blood loss up to 1499 ml; group 2 (n = 14) – blood loss from 1500 to 1999 ml; group 3 (n = 19) – blood loss 2000 ml and more. The following hemostasis parameters were determined: platelet count, prothrombin index, activated partial thromboplastin time (APTT), Claus fibrinogen level, international normalized ratio, and TEM parameters, including clotting time (CT), clot formation time (CFT), maximum clot firmness (MCF), and maximum clot firmness at 10 minutes (A10) on the EXTEM channels (a test in which recombinant tissue factor is used to activate the extrinsic coagulation pathway), FIBTEM (a test in which platelet activity is suppressed by cytochalasin D, which allows detecting fibrinogen deficiency or qualitative disturbances in fibrin polymerization), and INTEM (a test in which ellagic acid is used as a contact activator of the intrinsic coagulation pathway). Blood samples were collected before administration of blood components and products, tranexamic acid.

Results. Statistically significant differences were found for the fibrinogen level, MCF and A10 parameters on the FIBTEM channel depending on blood loss volume (p < 0.05), indicating a decrease in the quality of fibrin clot upon with increasing blood loss. Highly tight direct relationships were found between the fibrinogen, MCF and A10 values, demonstrating that with a decrease in the fibrinogen level at the time of bleeding by 1.0 g/L, a decrease in MCF by 3.802 mm (the resulting model explains 64.3 % of the observed variance), and A10 by 3.497 mm (the resulting model explains 64.1 % of the observed variance) should be expected. All patients whose blood loss volume reached 2000 ml and more were administered cryoprecipitate, the differences in the parameters were statistically significant between group 3 vs. group 1 and group 2 (p < 0.001). TEM parameters CT and CFT on the INTEM channel also correlated with blood loss volume and had a significant direct correlation between noticeable tightness (according to the Chaddock scale) between APTT and CT (ρ = 0.612; p < 0.001) as well as moderate tightness between APTT and CFT (rxy = 0.44; p = 0.017). The need for transfusion of fresh frozen plasma (FFP) and prothrombin complex concentrates (PCСs) arose with APTT more than 35 seconds in 77 % of cases (among all patients), with the CT parameter more than 260 seconds – in 63 % of cases and CFT more than 110 sec – in 63 % of cases, respectively; the differences in the indicators are significant while compared with those of patients requiring no introduction of FFP and PPC (p < 0.05). Based on controlled transfusion protocol, in group 1, in 57.9 % of cases it was possible apply no transfusion therapy; the differences in indicators are significant while comparing group 2 and group 3 (p < 0.05).

Conclusion. The use of the TEM method in the diagnostics of hemostasis disorders with PPH allowed for the differential and short-term application of pathogenetically justified therapy with blood components and preparations only in cases where it was required.

REVIEW ARTICLES

What is already known about this subject?

► Organic iron salts are of the lowest toxicity and hold top inte­rest for prevention and treatment of iron deficiency anemia (IDA).

► Little information regarding organic iron salt pharmacokinetics and pharmacodynamics is available.

► There are fundamental and clinical data indicating about effectiveness and safety of iron fumarate administration.

What are the new findings?

► All available studies regarding iron fumarate have been categorized, additionally providing comparative pharmacology of fumarate and other iron forms, effects on hemosiderosis, synergism between iron fumarate and other micronutrients as well as microbiome along with clinical applications of iron fumarate in IDA treatment of pregnant women.

How might it impact on clinical practice in the foreseeable future?

► Iron fumarate vs. iron sulfate causes less damage to tooth enamel.

► Vitamin-mineral complex preparations containing iron fumarate are characterized by fewer side effects and better adherence to IDA therapy in postpartum women.

230-249 650
Abstract

Introduction. The use of the safest and most effective methods for iron deficiency (ID) compensation is implicated in current therapy of iron deficiency anemia (IDA). Oral administration of iron salts with organic acid anions is an important field in IDA therapy and prevention. Iron fumarate, being a divalent iron salt and the fumaric acid anion (a tricarboxylic acid cycle metabolite), is absorbed in vivo via gene-encoded molecular mechanisms specialized to interact primarily with fumarate anion.

Aim: to systematize the data from fundamental and clinical studies on iron fumarate pharmacology for ID treatment using topological and metric methods of intellectual analysis.

Results. The results of systematization of studies on iron fumarate pharmacology (more than 500 articles) are presented along and performed categorization of all available publications. The results of the most essential research fields assessing iron fumarate pharmacology are described in detail: (1) comparative pharmacology of iron fumarate and other iron forms; (2) an effect of various iron salts on tissue hemosiderosis; (3) synergism between iron fumarate and folates and other micronutrients; (4) an effect of microbiome state and iron fumarate absorption improved by prebiotics; (5) clinical practice of using iron fumarate for IDA treatment of women in all age groups.

Conclusion. Fumarate-containing preparations are indicated in case where profound substrate-mediated support is required for pillar arms of aerobic and anaerobic energy metabolism ranging from mitochondria and cells to organismal level demanding to mobilize signal-regulatory adaptive reactions. Oral intake of fumarate salt preparations may exert milder and safer effect. In aerobic and hypoxic energy metabolism, which is typical for ID, fumarate salts may act as effective anti-stress and anti-hypoxic agents.

What is already known about this subject?

► Systemic inflammatory response syndrome (SIRS) and septic shock (SS) in newborns are associated with the activation of inflammatory and coagulation cascades resulting in multiple organ failure.

► Fetal inflammatory response syndrome (FIRS) plays a crucial role in the development of severe complications, including damage to the nervous, respiratory, and cardiovascular systems.

► Despite gaining deeper insights into molecular mechanisms, effective therapeutic strategies for the treatment of neonatal sepsis and SS remain underdeveloped.

What are the new findings?

► An updated perspective on the mechanisms linking inflammation and hemostasis is presented, including the impact of pro-inflammatory cytokines on coagulation.

► New FIRS and SS potential biomarkers enabling earlier identification of complication risks are described.

► The necessity of developing personalized therapeutic strategies based on molecular profiles of inflammatory response is emphasized.

How might it impact on clinical practice in the foreseeable future?

► Improving FIRS and SS diagnostics as well as understanding underlying mechanisms contributes to early therapy initiation and an increased level of favorable outcomes.

250-272 867
Abstract

The article is dedicated to outlining the pathogenic mechanisms, diagnostic criteria, and treatment of systemic inflammatory response syndrome (SIRS), thromboinflammation, and septic shock in fetuses and newborns. SIRS is a body hyperreaction to external stress involving biologically active molecules, cytokines such as tumor necrosis factor-alpha (TNF-α) and interleukin (IL) IL-1 so that a balance between inflammation and adaptive mechanisms becomes altered. Special attention is paid to fetal inflammatory response syndrome (FIRS). Here, we describe the broad impact of FIRS targeting vital organs and systems. The challenges in diagnosing and treating septic shock in newborns are discussed, highlighting a crosstalk between inflammation and hemostasis. Despite progress in understanding the molecular mechanisms underlying FIRS and sepsis, some obstacles in developing effective therapeutic strategies remain. This underscores a need for conducting targeted research to reduce morbidity and mortality related to thromboinflammation and septic shock.

What is already known about this subject?

► The causes of infertility include genetic, anatomical, endocrine, immunological and microbiological factors. One of the ways to overcome infertility is to use assisted reproductive technologies (ART), with overall effectiveness comprising about 45 %.

► Five vaginal community state types (CST) have been identified in the vaginal microbiome. CST1 is considered the most favo­rable for the onset of clinical pregnancy.

► The normal species composition of the uterine microbiota has not been defined. It is unknown whether the microorganisms detected are permanent uterine inhabitants or accidentally introduced due to transvaginal manipulation.

What are the new findings?

► New data on the role of Lactobacillus spp. and opportunistic microorganisms in the uterine and vaginal microbiome for successful pregnancy and repeated implantation failure (RIF) are presented.

► Among new methods to study an effect of the vaginal and uterine microbiome on ART outcomes, 16S rRNA sequencing, whole metagenomic sequencing, metabolomics, and cultureomics have been used.

► The microbiota of the female reproductive tract is able to affect local immune reactions in the uterine cavity, affecting embryo implantation.

How might it impact on clinical practice in the foreseeable future?

► Investigating reproductive microbiome will help to predict pregnancy success in ART programs, as well as to reduce infertility-related RIF number of microbiological etiology.

273-281 813
Abstract

Infertility is a high-priority medical and social issue, which prevalence reaches 15 % according to the World Health Organization. One of the methods for infertility treatment, which is often resorted to by sub-fertile couples, is the use of assisted reproductive technologies (ART). It is known that the microbiome of the uterine cavity and vagina can affect ART-related fertility potential. The normal vaginal microbiome is characterized by the dominance of Lactobacillus spp. representatives, which ensure the maintenance of optimal pH values and prevent pathogenic microbial penetration and multiplication. It is assumed that the normal endometrial microbiome is characterized by predominance of Lactobacillus spp., but relevant studies are prominently heterogeneous. According to the current hypothesis, the dominance of Lactobacillus spp. and, particularly, Lactobacillus crispatus, in the vagina and uterine cavity is associated with favorable reproductive outcomes in ART programs. Recurrent implantation failures are related to spreading of opportunistic microflora in such niches. Nevertheless, some authors have reported no direct correlation between Lactobacillus spp. level, presence of opportunistic microorganisms and favorable outcomes of ART programs, which underlies a need to conduct further large-scale studies.

What is already known about this subject?

► A high frequency of ARID1A gene mutations has been found in clear cell ovarian carcinoma (CCOC), endometrioid ovarian carcinoma and uterine body cancer, as well as in non-gynecological cancers, including colorectal carcinoma, gastric carcinoma, cholangiocarcinoma, Burkitt's childhood lymphoma and pancreatic cancer.

ARID1A mutations in oncological diseases are predominantly point-like and lead to downregulated protein expression and inactivation.

► As a transcription regulator, ARID1A may be involved in cancer progression. Mutations in the ARID1A gene are more common in gynecological tumors than in any other human tumor types, especially in clear cell ovarian cancer and endometrioid uterine carcinomas.

What are the new findings?

► Loss of ARID1A function may affect resistance to antitumor drugs, enhance cytotoxic response to radiation therapy and increase sensitivity of patients to chemotherapy.

► Mutations leading to loss of ARID1A function are widespread in CCOC being found in more than half of the cases. Loss of ARID1A function potetiates immune checkpoint blocker response. Endometriosis is a risk factor for CCOC, and many endometriosis samples exhibit ARID1A mutations.

ARID1A mutations are especially common in HPV-negative cervical cancer, and about 67 % of such patients show no response to chemotherapy or radiation therapy. Loss of ARID1A function may contribute to developing drug resistance.

How might it impact on clinical practice in the foreseeable future?

► The high frequency of ARID1A mutation in malignant tumors of the female reproductive system opens up unique opportunities for targeted preventive and therapeutic intervention.

► ARID1A can be used as a biomarker of precancerous diseases, as well as as a tool for predicting response to radiation therapy, immunotherapy and targeted therapies.

► Based on the results of the studies summarized in this review, future strategies for prevention and treatment of malignant neoplasms of the female reproductive system can be modified by taking into account ARID1A status.

282-298 1093
Abstract

Сhromatin remodeling tumor suppressor protein ARID1A (AT-rich interaction domain 1A) is coded by the ARID1A gene that is one of the most frequently mutated genes in human oncological diseases. Inactivating mutations in the ARID1A gene have a pronounced effect on cell survival, chemoresistance, transcription and cell cycle regulation. To date, a large number of studies have focused on assessing the effect of mutations leading to loss of ARID1A function on tumor emergence, progression and therapy resistance. The high frequency of ARID1A mutations in malignant tumors of the female reproductive system opens up unique opportunities for targeted preventive and therapeutic intervention. Clear cell ovarian carcinoma and uterine body cancer bearing ARID1A mutations do not respond well to standard chemotherapy proposing no current effective targeted therapy, which underlines a need for further research in the field. ARID1A can be used as a biomarker of precancerous diseases, as well as a tool for predicting a response to radiation therapy, immunotherapy and targeted therapies. Currently, clinical trials assessing several low molecular weight and epigenetic inhibitors are being conducted in tumors of the female reproductive system with ARID1A deficiency.

CLINICAL CASE

What is already known about this subject?

► Uterine rupture is a critical obstetric complication occurring during pregnancy or childbirth, characterized by high maternal and perinatal morbidity and mortality rates, primarily due to internal bleeding, antenatal/intrapartum fetal demise, hemorrhagic/pain shock, cardiac arrest, and disseminated intravascular coagulation.

► In recent decades, due to expanded indications for operative delivery, a uterine scar has become a primary risk factor for uterine rupture. Cases of spontaneous rupture at the scar site, in association with placenta accreta spectrum, significantly increase adverse outcomes for both mother and fetus.

► Rupture of the unoperated uterus during pregnancy is quite rare. The risk group includes multiparous women and those with a history of intrauterine manipulations such as dilatation and curettage (D&C) or uterine septum resection.

What are the new findings?

► It challenges the standard notion that uterine scarring is the primary risk factor for uterine rupture during pregnancy. While collecting histories from unoperated pregnant women, special attention should be paid to risk factors that may lead to spontaneous uterine rupture.

► Spontaneous uterine rupture can occur at any point in pregnancy without traumatic or violent factors, even in the absence of the known risk factors. Timely diagnostics and emergency assistance can reduce maternal and perinatal morbidity and mortality.

How might it impact on clinical practice in the foreseeable future?

► Increased attention and vigilance towards multiparous women with complicated obstetric histories as a risk group for spontaneous uterine rupture during pregnancy is required. Primary health care providers should educate women about family planning and contraception to maintain an optimal interpregnancy interval.

► Pregnant women in the risk group for spontaneous uterine rupture are advised to undergo placental vessel ultrasound Doppler examination and, if necessary, magnetic resonance imaging to rule out placenta accreta spectrum.

299-305 835
Abstract

Spontaneous uterine rupture during pregnancy is a life-threatening complication that predominantly occurs in the third trimester. A scar resulting from a prior cesarean section represents the primary risk factor for uterine rupture. It is one of the most severe complications in obstetrics, accompanied by bleeding, severe traumatic and hemorrhagic shock, and high perinatal mortality for both the fetus and the woman. Cases of uterine rupture without commonly accepted risk factors, regardless of parity or gestational age, have been described in the literature. Here, we present a clinical case of a complete uterine rupture occurred outside a medical facility at gestational age of 25 weeks in a multiparous woman with a complicated obstetric-gynecological history, lacking uterine scar. This was accompanied by severe hemorrhagic shock, cardiac arrest, and antenatal fetal demise. High-quality specialized care resulted in a favorable outcome for the mother.

FROM HISTORY

306-311 447
Abstract

Today, understanding physiology of the placental period during normal childbirth, its management, identifying a moment of placental separation and methods for extracting separated and freely-lying birth canal placenta have been well documented. Nevertheless, the history of obstetrics and gynecology keeps everyday work secrets. Here, we would like to uncover one of them to the AGR readers primarily aimed at describing the "unknown" along with the "well-known" moment and restore "historical justice".

EVENTS